Answers are grounded in this paper and cite their sources.
Patient safety is a primary priority in the conduction of retinal gene therapy trials. An understanding of risk factors and mitigation strategies for post-procedure complications is crucial for the optimization of gene therapy clinical trial protocols. In this review, we synthesize the literature on ocular delivery methods, vector platforms, and treatment-emergent adverse effects in recent gene therapy clinical trials for inherited retinal diseases.
No takes yet. Share an insight, caveat, or question.
Nuzbrokh et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: